Trial Profile
Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Aug 2017
Price :
$35
*
At a glance
- Drugs Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms STRIB-PEP
- 26 Jul 2017 Results of substudy presented at the 9th International AIDS Society Conference on HIV Science
- 20 Feb 2017 Status changed from not yet recruiting to completed.
- 06 Aug 2014 New trial record